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 31 
Abstract  32 
Objectives. Carbapenemases are the most important mechanism responsible for 33 
carbapenem resistance in Enterobacteriaceae. Among carbapenemases, OXA-48 34 
presents unique challenges as it is resistant to β-lactam inhibitors. Here, we test the 35 
capacity of the compound LN-1-255, a 6-alkylidene-2`-substituted penicillanic acid 36 
sulfone, to inhibit the activity of the carbapenemase OXA-48. 37 
Methods. The OXA-48 gene was cloned into Klebsiella pneumoniae and 38 
Escherichia coli in order to obtain MICs in presence of inhibitors (clavulanic acid, 39 
tazobactam, and sulbactam) and LN-1-255. OXA-48 was purified and state-state 40 
kinetics were performed with LN-1-255 and tazobactam. The covalent binding mode of 41 
LN-1-255 with OXA-48 was studied by docking assays. 42 
 Results. Both OXA-48 producing clinical and transformant strains display 43 
increased susceptibility to carbapenem antibiotics in the presence of 4 mg/L of LN-1-44 
255 (2-32-fold increased susceptibility) and 16 mg/L of LN-1-255 (4-64-fold increased 45 
susceptibility). Kinetics assays demonstrated that LN-1-255 is able to inhibit OXA-48, 46 






 and a slow deacylation rate 47 




. Inhibitory concentration 50% (IC50) was 3 nM for LN-1-255 and 48 
1.5 µM for tazobactam. Lastly, turnover rate was 500-fold lower for LN-1-255 than for 49 
tazobactam. Docking assays confirmed the anchored of LN-1-255 on the active binding 50 
site of OXA-48. 51 
Conclusions. In these studies, carbapenem antibiotics used in combination with 52 
LN-1-255 are effective against the carbapenemase OXA-48, an important emerging 53 
mechanism of antibiotic resistance. This provide stimulus for further investigations to 54 
maximize the efficacy of penicillin sulfone inhibition of class D plasmid-carried 55 
Enterobacteriaceae carbapenemases.  56 
 57 
 58 
  59 
Introduction 60 
Antimicrobial resistance rates on bacterial pathogens have steadily increased in 61 
recent years, and is now defined as a world health crisis by major international 62 
agencies.
1
 Enterobacteriaceae are a bacterial family in which significantly increased 63 
rates of resistance have been observed. The main resistance mechanism - as for Gram-64 
negative bacteria in general - is β-lactamase-mediated hydrolysis of antimicrobial 65 
compounds.
2
 The prevalence and plasmid-mediated dissemination of β-lactamase genes 66 
are an important clinical challenge. Until the first decade of the XXI century, the more 67 
clinically relevant β-lactamases were the extended spectrum β-lactamases (ESBL) and 68 
the chromosomal and plasmid-mediated cephalosporinases (AmpC).
3
 Although 69 
carbapenem antibiotics remained active against β-lactamase-expressing bacteria, in 70 
recent years there has been an increase in the number of β-lactamases able to hydrolyze 71 
carbapenems. Of these enzymes, denoted „carbapenemases‟, a growing group of OXA 72 
enzymes - the class D β-lactamases - is especially relevant.
4,5
 These carbapenemases are 73 
mostly observed in Acinetobacter baumannii,
5,6
 but the frequency of OXA-48 74 
expression is increasing in Enterobacteriaceae,
7
 largely in Klebsiella pneumoniae, and 75 
in Escherichia coli, Enterobacter cloacae, Citrobacter freundii, and Providencia 76 
rettgeri. 
8-13
  77 
An important epidemiological change is occurring nowadays, a rapid increase of 78 
the number of isolates of carbapenemase-producing Enterobacteriaceae, mainly K. 79 
pneumoniae. 
14
 Thus, numerous hospital outbreaks of OXA-48-carrying 80 
Enterobacteriaceae have been reported worldwide 
8,10,15
 and the rising numbers of 81 
positive isolates reported showing the OXA-48 the most frequently detected 82 
carbapenemase in France, Belgium and Malta.12,16 The rapid increase of such 83 
carbapenem-resistant isolates is facilitated by two main routes of dissemination: 84 
horizontal transfer of plasmids encoding OXA-48, and the vertical dissemination of 85 
successful clones.
17,18
 The blaOXA-48-like genes are always encoded in transposons 86 
Tn1999, plasmid-borne, broad-host-range self-conjugative, and with a high conjugation 87 
rate IncL/M-type plasmid.
19
 Along with KPC- and NDM-type carbapenemases, OXA-88 
48 represents a major obstacle in the preservation of carbapenem efficacy against 89 
serious bacterial infections in Enterobacteriaceae. 90 
Currently, few novel options for treatment of such multi-drug resistant bacterial 91 
strains exist. One of the more promising avenues is the combination of β-lactam 92 
antibiotics with β-lactamase inhibitors, but currently commercial inhibitors are not 93 
effective against class D carbapenemases. Unlike class A enzymes, class D 94 
carbapenemases are not inhibited by β-lactamase inhibitors such as clavulanic acid, 95 
sulbactam or tazobactam.
2
  Bacteria harboring and expressing these genes are resistant 96 
to most antibiotics, with few exceptions (e.g. tigecycline and colistin) although it is also 97 
increasing the resistance rates to these antimicrobials.
20-22
 Considering that carbapenems 98 
are the main drug of choice to treat multi-resistant hospital acquired infections, the 99 
development of efficient inhibitors of OXA-48 enzymes is urgently needed in order to 100 
maintain the efficacy of β-lactam antibiotics .
8,23
 An example is the avibactam, which 101 
has generated great interest among the medical community and  has been very recently 102 
approved by the FDA for treating complicated infections caused by antibiotic resistant-103 
pathogens.
24
 It demonstrates activity against OXA-48, however not against the class D 104 
carbapenemases of Acinetobacter baumannii, such as OXA-23 or OXA-24/40, main 105 
responsible of carbapenem-resistance in this MDR pathogen.
25,26
 Buynak et al. have 106 
designed several β-lactamase inhibitors, 
27
 of which the compound LN-1-255 represents 107 
a promising candidate in the quest for new OXA β-lactamase inhibitors. The design and 108 
synthesis of this 6-alkylidene-2´-substituted penicillin sulfone was previously 109 
reported,
28
 and has previously demonstrated the efficacy of this compound to inhibit the 110 
class D carbapenemase OXA-24/40 of A. baumannii (implicating the hydrophobic 111 
barrier established through an arrangement of the Tyr112 and Met223 amino acids). 112 
This barrier is not present in the OXA-48 enzyme, similarly to OXA-10, another class D 113 
β-lactamase which lacks carbapenem hydrolytic activity.
29,30
 The LN-1-255 compound 114 
is also able to inhibit class A β-lactamases, such as SHV-1 and SHV-2.
31
 However the 115 
potential of LN-1-255 as an inhibitor of Enterobacteriaceae-derived class D 116 
carbapenemases has not yet been evaluated. Here, we analyze the capacity of LN-1-255 117 
to inhibit such an OXA-48 carbapenemase, similarly to what happens with the OXA-118 
24/40 carbapenemase. Also we study the synergy of this inhibitor with carbapenems 119 
against clinical isolates of K. pneumoniae and transformants of E. coli and K. 120 
pneumoniae.   121 
 122 
Materials and methods  123 
Bacterial strains, culture media and plasmids 124 
For microbiological studies, the blaOXA-48 gene was amplified from a clinical 125 
strain of K. pneumoniae derived from an outbreak in our hospital (A Coruña Hospital, 126 
Spain), which began in 2013 and continues until today, and has affected more than 160 127 
patients. Epidemiological studies demonstrate that the outbreak resulted from the 128 
dissemination of a single clone of serotype ST-15. All carbapenem-resistant strains 129 
involved in the outbreak harbor the same plasmid, which carries the OXA-48 130 
carbapenemase gene.
32
 The strains utilized to transform the genetic constructions to 131 
study the MICs were obtained during previous studies, and have porin deficits: E. coli 132 
J53 ΔompC/F lacks porins OmpC and OmpF, 
33
 and K. pneumoniae ΔompK35/36 lacks 133 
porins OmpK35 and OmpK36.
34
 These strains were chosen in order to increase the 134 
genetic background of resistance upon transformation. All strains were cultured in Luria 135 
Bertani (LB) medium at 37°C and stored at -80ºC until analysis in LB medium 136 
containing 15% glycerol. When necessary the LB medium was supplemented with 137 
ampicillin and/or kanamicyn (Sigma-Genosys Ltd, UK). 138 
 139 
Susceptibility testing antibiotics and inhibitors. 140 
OXA-48 was amplified from genomic DNA, using Expand High Fidelity PCR 141 
System (Roche, Basel, Switzerland) and a primer pair containing recognition sites for 142 
the restriction enzymes BamHI (5´-AAAGGATCCATGCGTGTATTAGCCTTAT-3‟) 143 
and EcoRI (5´-AAAGAATTCCTAGGGAATAATTTTTTCCTGTTT-3‟). The 144 
amplified DNA fragment was then digested with BamHI and EcoRI (Fermentas, Glen 145 
Burnie, Ma, USA) and ligated to a BamHI/EcoRI digested pBGS18 plasmid.
35
 This 146 
plasmid construct (pBGS18-OXA-48) was used to transform the strain E. coli DH5α for 147 
subcloning and then transformed in E. coli J53 ΔompC/F, and K. pneumoniae 148 
ΔompK35/36. Antibiotic susceptibility profiles were determined by microdilution 149 
following CLSI criteria.
36
 Susceptibility to imipenem, meropenem, and ertapenem 150 
(Sigma-Genosys Ltd, UK), in combination with the inhibitor LN-1-255 at fixed 151 
concentrations of 4 or 16 mg/L, was determined. For comparison, the inhibitor 152 
tazobactam was used at the same concentrations, as well as sulbactam and clavulanic 153 
acid (Sigma-Genosys Ltd, UK) at 4 mg/L. Etest of carbapenems (Biomerieux, Marcy 154 
l'Etoile, France) in conjunction with inhibitors were performed on Mueller Hinton II 155 
agar plates to confirm MICs. The MICs reported are the mean of three independent 156 
replicates. LN-1-255 was prepared in the laboratories of the Southern Methodist 157 
University, Dallas, USA, as described previously.
27
 The chemical structures of LN-1-158 
255 and tazobactam are shown in Figure 1. 159 
Synergy studies were also performed using the checkerboard method using both 160 
K. pneumoniae strains. Synergy of imipenem (range of 0.12-256 mg/L) in absence and 161 
presence of LN-1-255 at 16 mg/L was combined with important treatment option 162 
against MDR pathogens, such as tigecycline, colistin and amikacin (range 0.12 -256 163 
mg/L). The fractional inhibitory concentration index (FIC) was calculated and was 164 
interpreted as follows: FICindex of ≤0.5, synergy; FICindex of >0.5 to 4, no interaction.
37
  165 
 166 
Purification of OXA-48 167 
For kinetic studies, blaOXA-48 was directionally cloned into the p-GEX-6p-1 168 
plasmid for expression and purification (GE Healthcare, Little Chalfont, United 169 
Kingdom). As above, this gene was amplified from genomic DNA, using Expand High 170 
Fidelity PCR System (Roche, Basel, Switzerland) with a primer pair containing 171 
recognition sites for the restriction enzymes BamHI (5´-172 
AAAGGATCCAAGGAATGGCAAGAAAACAAA-3‟) and EcoRI (5´-173 
AAAGAATTCCTAGGGAATAATTTTTTCCTGTTT-3‟). The amplified DNA 174 
fragment was then digested with BamHI and EcoRI and ligated to BamHI/EcoRI 175 
digested p-GEX-6p-1. The recombinant plasmid was electropored in E. coli BL21 176 
(DE3) - which has a proteases deficit - to generate the fusion protein GST/OXA-48. 177 
This protein was purified to homogeneity using the GST Gene Fusion System 178 
(Amersham Pharmacia Biotech, Europe GmbH) in conjunction with the manufacturer´s 179 
instructions. The purification was confirmed using SDS-PAGE gels, as a band of 180 
approximately 29 KD (>95% purity) and later identification with MALDI-TOF/TOF 181 
spectrometer (Bruker Daltonics, Billerica, MA). 182 
 183 
Kinetic experiments.  184 
Kinetic constants of OXA-48 β-lactamase were determined by continuous assays 185 
at room temperature, 25 ºC, using a Nicolet Evolution 300 spectrophotometer (Thermo 186 
Fisher Scientific, Waltham, MA, USA). Each experiment was performed at least in 187 
triplicate, in 50 mM sodium phosphate with 20 mM of sodium bicarbonate,
38
 and using 188 
0.2 and 1.0 cm pathlenght cuvettes. Measurements of hydrolysis were performed with 189 
nitrocefin (NCF) (Oxoid, Hampshire, UK) at 590 nM, imipenem and ertapenem, both to 190 
299 nM. Measurements of inhibition were performed in the presence of LN-1-255 and 191 
tazobactam, using nitrocefin at 200 µM as the reporter substrate. The kinetics assays 192 
were previously described 
30,39,40
 and are briefly explained below. Vmax, kcat and Km were 193 
determined by initial velocity kinetic analysis. The data were fitted to the Michaelis-194 
Menten equation (Equation 1) using nonlinear least-squares regression analysis. 195 
v = Vmax [S] / (Km + [S])       (Eq. 1) 196 
The inhibitor concentration resulting in 50% reduction of nitrocefin hydrolysis 197 
after 10 min of pre-incubation of the enzyme and inhibitor at 25 °C was denoted as the 198 
IC50, as previously described.
30
 199 
The apparent Km for tazobactam and LN-1-255 was obtained as a competitive 200 
inhibition constant (Ki app) in the presence of nitrocefin.
40
 Inverse initial velocities (1/vo) 201 
were plotted against inhibitor concentration ([I]) to obtain linear plots. Initial velocity 202 
(v0) was determined by Equation 2. 203 
v0 = (Vmax x [S]) / [(Km NCF) x (1 + [I] / Km NCF) + [S]       (Eq. 2) 204 
Ki app was determined by dividing the value of the y-intercept of the linear plot by the 205 
slope, and corrected for nitrocefin affinity using Equation 3. 206 
Ki app (corrected) = Ki app (observed) / [1 + ([S] / Km NCF)]      (Eq. 3) 207 
The inhibitor complex inactivation rate (kinact) in the presence of nitrocefin was 208 
measured and KI determined as previously described.
41
 The kobs values were determined 209 
using non-linear least squares fit of the data, employing Origin 7.5
®
 software and 210 
Equation 4.  211 
A = A0 + vf x t + (v0 – vf) x [1 – exp(-kobst)] / kobs    (Eq. 4) 212 
Here, A is absorbance, v0 (expressed in variation of absorbance per unit time) is initial 213 
velocity, vf is the final velocity, and t is time. Each kobs was plotted against [I] and a fit 214 
performed to determine kinact and KI using Equation 5. The KI value was corrected using 215 
equation 3. 216 
kobs = kinact [I] / (KI + [I])     (Eq. 5) 217 
The k2/K (observed) was determined as the slope of the line obtained by plotting 218 









) + 1)    (Eq. 6) 220 
The koff for LN-1-255 was performed using a jump dilution method followed by 221 
continuous assays, as previously described.
42
 Briefly, 1 µM of enzyme was incubated 222 
with 10 µM of LN-1-255 for 5 minutes at 37 ºC, the reaction solution was diluted 223 
40,000-fold in assay buffer, and hydrolysis of 200 µM of nitrocefin was measured in 224 
500 µL of reaction solution. Reaction solutions without OXA-48, or containing OXA-225 
48 without LN-1-255 were used as controls.  226 
The Kd (dissociation constant) was determined by equation 7. 227 
Kd = koff / (k2/K)    (Eq. 7) 228 
The partition ratio (kcat /kinact) or turnover number (tn) is defined as the ratio of 229 
inhibitor enzyme (I:E) necessary for >90% inhibition of nitrocefin hydrolysis.
30
 The tn 230 
values were determined after 5 hours of incubation with increasing concentrations of 231 
inhibitor and 10 nM of enzyme, varying the molar ratios of I:E. Longer incubation 232 
times could not be used due to enzyme instability and loss of activity. Incubations were 233 
done in a final reaction volume of 500 µL and 200 µM nitrocefin added immediately 234 
before measure, in order to determine the residual enzyme activity during 60 seconds.  235 
 236 
Docking studies  237 
The covalent binding mode of LN-1-255 with OXA-48 from K. pneumoniae was 238 
studied using GOLD 5.2
43 
and the enzyme geometries found in the crystal structure of 239 
OXA-48/avibactam adduct (PDB 4S2K,
44
 2.1 Å). Water molecules and ligands were 240 
removed from crystal structure. Ligand geometry was minimized using the AM1 241 
Hamiltonian as implemented in the program Gaussian 09
45 
and used as MOL2 files. The 242 
ligand was docked in 25 independent genetic algorithm (GA) runs, and for each of these 243 
a maximum number of 100000 GA operations were performed on a single population of 244 
50 individuals. Covalent docking was applied between the catalytic Ser-81 (oxygen 245 
atom side chain) and the carboxylate group (oxygen atom) of the indolizine derived 246 
obtained after covalent modification of OXA-24/40 from A. baumannii with LN-1-247 
255.
26
 Operator weights for crossover, mutation and migration in the entry box were 248 
used as default parameters (95, 95, and 10, respectively), as well as the hydrogen 249 
bonding (4.0 Å) and van der Waals (2.5 Å) parameters. The position of avibactam in the 250 
crystal structure was used to define the active-site and the radius was set to 7 Å. The 251 
“flip ring corners” flag was switched on, while all the other flags were off. The GOLD 252 
scoring function was used to rank the ligands in order to fitness. 253 
  254 
Results 255 
Antimicrobial susceptibility assays 256 
To determine the synergy of LN-1-255 with diverse carbapenems against OXA-257 
48, in vitro susceptibility to imipenem/LN-1-255, meropenem/LN-1-255, and 258 
ertapenem/LN-1-255 were compared to susceptibility to these carbapenems in 259 
combination with the classical inhibitors clavulanic acid, sulbactam and tazobactam. 260 
(Results are shown in Table 1). Type-strains without any resistance mechanism were 261 
not presented because they showed very low MIC values to carbapenems when OXA-262 
48 was cloned into them (data not shown), thus the used transformants were porins-263 
deficient. As discussed above, carbapenem MICs were investigated using 4 mg/L of all 264 
inhibitors, and 16 mg/L of LN-1-255 and tazobactam. Clavulanic acid and sulbactam 265 
could not be tested at 16 mg/L with K. pneumoniae strains or at 4 mg/L with E. coli 266 
strains, as the MICs of these two inhibitors using K. pneumoniae strains were 32-256 267 
mg/L, and using E. coli strains were 16 mg/L for sulbactam and 16-128 mg/L for 268 
clavulanic acid. This intrinsic susceptibility to sulbactam and clavulanic acid prevents 269 
clear observation of OXA-48 inhibition. 270 
Neither sulbactam nor clavulanic acid at 4 mg/L were able at to inhibit OXA-48 271 
activity at any dilution in the performed assays. At 4 mg/L, tazobactam was able to 272 
inhibit OXA-48 activity in only one dilution, and otherwise did not reduce MICs 273 
compared to carbapenems alone. At 4 mg/L, LN-1-255 was able to reduce carbapenem 274 
MICs 2-32-fold. These differences were amplified when 16 mg/L of LN-1-255 or 275 
tazobactam were used.  276 
The clinical K. pneumoniae isolate displayed an imipenem MIC of 64 mg/L, 277 
decreased 16-fold to 4 mg/L in the presence of LN-1-255, and 2-fold to 32 mg/L in the 278 
presence of tazobactam. Similarly, transformed K. pneumoniae ΔompK35/36 displayed 279 
an imipenem MIC of 128 mg/L, decreased 8-fold to 16 mg/L, in the presence of 16 280 
mg/L of LN-1-255, but zero-fold in the presence of 16 mg/L of tazobactam.  281 
More pronounced differences were observed in transformed E. coli ΔompC/F, 282 
with 8-, 32-, and 64-fold reductions in imipenem, meropenem, and ertapenem MICs in 283 
the presence of LN-1-255, compared to a 2-fold MIC decrease in the presence of 284 
tazobactam. The remaining data are shown in Table 1. Using transformed E. coli DH5α, 285 
the effect of 4 mg/L LN-1-255 on carbapenem MIC was also more significant that the 286 
effect of 4 mg/L tazobactam. However, at inhibitor concentrations of 16 mg/L, this 287 
transformed strain was highly susceptible to the antimicrobial effect of these 288 
combinations, precluding quantitative analysis of effect sizes (data not shown). 289 
By checkerboard method the combination of imipenem/LN-1-255 or imipenem 290 
alone were tested against tigecycline, colistin and amikacin. The presence of LN-1-255 291 
decreased one dilution the MIC at tigecycline and amikacin in the K. pneumoniae 292 
clinical strain, and also one dilution at amikacin in the ΔompK35/36 mutant. However 293 
the FICindex was > 0.5, no synergy was observed with these antimicrobials. (Data not 294 
shown).  295 
 296 
Kinetics and inhibition studies 297 
Kinetic properties substrate hydrolysis by OXA-48 are shown in Table 2. The 298 
protein concentration used on biochemical studies was 1.9 mg/mL. Similar Km values 299 
were observed for both carbapenems tested, imipenem and ertapenem, and for nitrocefin 300 
(60-123 µM), but pronounced differences were observed in hydrolysis velocity (kcat) for 301 
these substrates. When converted to catalytic efficiency, this value was 10-fold higher 302 




, respectively) while the 303 




) hydrolysis was 192-fold higher than that 304 
of imipenem.  305 
The OXA-48 inhibitory activities of LN-1-255 and tazobactam were determined 306 
and are summarized in Table 3. Using nitrocefin as the indicator substrate, LN-1-255 307 
showed inhibitory activity at much lower concentrations than tazobactam. Thus the Ki 308 
app - analogous to the Km for inhibitors - showed a higher affinity between the 309 
carbapenemase and LN-1-255 than between the carbapenemase and tazobactam (Ki app = 310 
0.17 and 30 µM, respectively).  311 
In order to determine kinact and thus inactivation efficiencies (kinact  /KI) of LN-1-312 
255 and tazobactam, progress curves were fitted to Equation 3 to obtain kobs values 313 
(Figure 2). These kobs values were plotted against concentrations of both inhibitors, and 314 
indicated a faster acylation at lower concentrations of LN-1-255 than of tazobactam. 315 
However, in the case of LN-1-255, this determination could not be completed due to an 316 
inability to achieve the maximum rate. Instead, k2/K was determined as an 317 






). The kinact  /KI of 318 




, showing an OXA-48 inactivation efficiency of more than 319 
33-fold lower than that of LN-1-255. Similarly, IC50 was much lower for LN-1-255 320 
(0.003 µM) than for tazobactam (1.5 µM), about 500-fold lower, indicating a higher 321 
relative efficacy of LN-1-255. Separate experiments (koff) indicated that the off rate of 322 




, representing a slow return of carbapenemase activity, with a 323 
residence time half-life (t1/2) of 16.5 min (Figure 3). In the case of tazobactam, an 324 
irreversible inhibitor, it was not possible to determine the off-rate. 
46
  325 
Lastly, in determining the partition ratio (tn) of LN-1-255 and tazobactam, the 326 
data showed a relative I:E significantly lower for LN-1-255 (tn = 2) than for tazobactam 327 
(tn =1000), indicating a 90% inhibition of OXA-48 at much lower concentration 328 
(approximately 500-fold) of LN-1-255 than of tazobactam (Figure 4). 329 
 330 
Docking studies 331 
As for previously reported OXA-48/avibactam adduct (PDB 4S2K,
38
 2.1 Å, Figures 5A 332 
and 5C), our docking studies showed that the indolizine adduct obtained after covalent 333 
modification of the catalytic Ser70 by LN-1-255 would also interact with residues Arg-334 
250, Lys-208, Tyr-211 and Thr-209 (Figures 5B and 5D). Specifically, the carboxylate 335 
group of the modified ligand would be anchored in the active site by electrostatic 336 
interactions with the guanidinium group of Arg-250 and the -amino group of Lys-208 337 
and hydrogen-bonding interaction with the hydroxyl group of Thr-209. In addition, the 338 
sulfinate group would establish an electrostatic interaction with the guanidinium group 339 
of Arg-250 as well as the carboxylate group of the ester linkage would interact by 340 
hydrogen-bonding with the NH main chain amide of Tyr-211. In contrast, our molecular 341 
docking studies predict that the catechol side chain would be more flexible. One of the 342 
phenol groups of the catechol moiety would interact by hydrogen-bonding with the -343 
amino group of Lys-208. This catechol moiety would partially occupy the large pocket 344 
close to the active site.  345 
 346 
Discussion 347 
Carbapenem-hydrolyzing class D β-lactamases can confer resistance to 348 
carbapenems, mostly in A. baumannii or Enterobacteriaceae with OXA-24/40 and 349 
OXA-48 as respective examples of such enzymes, limiting therapeutic options for 350 
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infection with these pathogens.
20,21
 The increasing number of clinical isolates and 351 
outbreaks of strains carrying class D carbapenemases underscores the need for new β-352 
lactamase inhibitors that can restore carbapenem efficacy. The penicillin sulfone 353 
inhibitor LN-1-255 was developed by Buynak et al. as a novel inhibitor of β-354 
lactamases.
28
 Initially, LN-1-255 was shown to be effective in inhibiting class A β-355 
lactamases,
31
 and, subsequently, class D enzymes.
29,30
 Similarly to OXA-24/40, 356 
carbapenem MICs in the presence of LN-1-255 were more significantly reduced when 357 
16 mg/L rather than 4 mg/L of LN-1-255 were used.
30
  358 
We have thus observed inhibition of OXA-48 carbapenemases, both in a clinical 359 
isolate of K. pneumoniae and in porin-deficient transformed K. pneumoniae and E. coli 360 
strains. Depending on which carbapenem was used, we obtained 2- to 64-fold 361 
reductions in carbapenem MICs. However, in most cases, use of the classical inhibitors 362 
(clavulanic acid, sulbactam and tazobactam) did not alter carbapenem MICs. These 363 
results are consistent with those obtained in similar studies on OXA-24/40 inhibition, 364 
where carbapenem MICs decreased 8- to 32-fold in the presence of LN-1-255, but only 365 
up to 2-fold in the presence of tazobactam.
30
 In this study the porin deficit in K. 366 
pneumoniae decreased slightly the efficacy of LN-1-255 (compared with the clinical 367 
strain) when combined with imipenem and ertapenem, however increased the efficacy 368 
when combined with meropenem, decreasing one fold the MIC. Thus it seems that LN-369 
1-255 is able to pass through the outer membrane, despite the porin deficit. In fact, this 370 
inhibitor was designed with a catecholic functionality that resembles a natural bacterial 371 
siderophore, enabling it to utilize the iron uptake system to traverse the outer 372 
membrane.
28    373 
The carbapenem hydrolysis kinetics of OXA-48 (Km and kcat) are largely 374 
concordant with those previously published by Poirel et al. 
47,48
 LN-1-255 was highly 375 
effective at inhibiting OXA-48 β-lactamase. LN-1-255 demonstrated a 33-fold higher 376 













, respectively. The inhibition due to LN-1-255 is characterized by a high binding 378 
affinity, with Ki = 0.17 µM and IC50 = 0.003 µM, which are respectively 180 and 500-379 
fold lower than those yielded using tazobactam. The off rate of  LN-1-255 was 380 




, yielding an enzyme reactivation half-life of 381 
16.5 min. Lastly, a partition rate (tn) of 2 for LN-1-255 compares very favorably to the 382 
more than 1000 for tazobactam required for 90% inactivation of OXA-48. These data 383 
likely indicate that LN-1-255 molecules are more slowly hydrolyzed by OXA-48 than 384 
tazobactam molecules.    385 
Regarding the A. baumannii OXA-24/40 carbapenemase, LN-1-255-mediated 386 
inhibition which was previously tested by our group, proved to be similar to the binding 387 
affinity of LN-1-255 for OXA-48, with Ki app = 0.7 µM and 0.17 µM, respectively. LN-388 













 for OXA-24/40 
30
. The crystal 390 
structure of both carbapenemases  has been previously determined, OXA-48 by 391 
Disquiet et al 
49
 and OXA-24/40 by our group.
50
 These two β-lactamases were the first 392 
class D carbapenemase crystal structures published and may be considered as two 393 
different carbapenemase models: although they share a common evolutionary origin, 394 
they eventually acquired their carbapenemase activity through distinct evolutionary 395 
pathways. Significant differences in the size and shape of their active sites are evident. 396 
OXA-24/40 presents a “hydrophobic barrier” (consisting of Tyr-112 and Met-223) 397 
covering the active site, which is implicated in correct orientation of small substrates, 398 
such as the carbapenems. However, this is not a conserved structure in the OXA 399 
carbapenemases, and OXA-48 lacks this tunnel-like structure. By contrast, OXA-48 400 
displays more homology with OXA-10, which is not a carbapenemase but is highly 401 
active in hydrolysing oxacillin. This ability is shared by OXA-48 but not OXA-402 
24/40.
30,49
  Despite these important differences, the compound LN-1-255 was able to 403 
inhibit both enzymes (OXA-24/40 and OXA-48) in the nM range. Later, De Luca et al. 404 
51
 showed that the small β5-β6 loop of OXA-48, close to the active site, is implicated in 405 
OXA β-lactamase ability to hydrolyze carbapenems by facilitating movement of the 406 
deacylating water molecule towards the acylated catalytic Ser-70 residue. The relevance 407 
of this loop has been confirmed, and is present in OXA-23, OXA-24/40 and OXA-48 408 
carbapenemases, meanwhile it present significant structural differences in OXA-10 β-409 
lactamase.
49,51
 This suggests that LN-1-255 is interacting with this loop to prevent 410 
carbapenem access to the active site of the carbapenemases. However, further structural 411 
and biochemical work is necessary to identify the precise inhibition mechanism.  412 
When comparing our results with those obtained by Ehmann et al. studying 413 













of avibactam, 71-fold lower). 415 




) compared with the off rate of 416 
LN-1-255 (7 x 10
-4 s-1), resulting in a 60-fold higher avibactam half-life.52 Thus the time 417 
half-life of 16.5 minutes of LN-1-255 could significant a drawback if used in the 418 
treatment in infections. How these data kinetics data affect to the clinical impact of 419 
these inhibitors is an issue that should be studied in experimental models of infection in 420 
the near future. 421 
Figure 5 represents avibactam and LN-1-255 at the active binding site of OXA-422 
48, the docking of LN-1-255 on the active site supports the inhibitory role of this 423 
compound. The LN-1-255 is anchored to OXA-48, similarly to the structure of 424 
avibactam and OXA-48 published by King and Strynadka
44
. Furthermore, although 425 
avibactam is able to inhibit OXA-48, it poorly inhibits OXA-24/40 of A. baumannii, in 426 
contrasting to LN-1-255.
26
  Structurally, it has been suggested that the inhibition 427 
efficiency of LN-1-255 is mainly due to: (1) the presence of the catechol moiety that 428 
facilitates entry through the outer membrane via the iron-uptake cell pathway, and (2) 429 
the incorporation of a (2-pyridyl)methylene group at C6 in the sulbactam core that 430 
results with the formation of an heterocyclic (indolizine) ester derivative that is resistant 431 
to hydrolysis.
26
 In spite of the high stability of these type of heterocyclic esters, LN-1-432 




) against OXA-48 from K. pneumoniae 433 




). It has been suggested that avibactam does not 434 
decompose via a hydrolytic mechanism of the carbamoyl linkage with the catalytic 435 
serine. Instead, it seems to occur via regeneration of the diazobicyclooctane moiety. We 436 
consider that, in addition to that, there are some differences in the binding mode of both 437 
modified ligands that could also contribute to the lower stability of the OXA-48/LN-1-438 
255 adduct than the corresponding OXA-48/avibactam. Comparison of the binding 439 
mode of the modified avibactam shown in the crystal structure of OXA-48/avibactam 440 
adduct (PDB 4S2K)
44
 and the predicted binding mode of the corresponding OXA-441 
48/LN-1-255 adduct obtained by molecular docking studies revealed that both adducts 442 
interact with mainly the same active site residues, specifically, Arg-250, Lys-208, Tyr-443 
211 and Thr-209. However, as illustrated in Figure 5, there are some differences in the 444 
binding contacts of the groups that most contribute to anchor the ligand in the active 445 
site, the sulfate and sulfinate/carboxylate groups that might explain their different 446 
behaviour. While the sulfate group in the avibactam adduct is deeply anchored in the 447 
active site through a salt bridge with Arg-250 and a hydrogen-bonding with Thr-209 448 
side chain (Figure 5C), the sulfinate group in the modified LN-1-255 only interacts by 449 
electrostatic interaction with Arg-250 (Figure 5D). We consider that the latter is 450 
consequence of the lack of the hydrophobic barrier present in OXA-24/40, which 451 
involves mainly residues Tyr-112 and Met-223.
30
 In this case, the carboxylate group of 452 
the modified LN-1-255 interacts by hydrogen-bonding with the phenol group of Tyr-453 
112. As a consequence, the sulfinate group can be located pointing inwards. As in the 454 
crystal structure of OXA-48/avibactam adduct, the latter group would interact by a salt 455 
bridge with the guanidinium group of Arg-261 and hydrogen-bonding with Ser-128 side 456 
chain. These binding differences might account in the overall different stability of the 457 
two adducts as experimentally observed (on and off rates).  458 
Because of the structural and mechanistic differences among class D 459 
carbapenemases,
49
 this area of drug discovery requires further studies to identify 460 
additional inhibitors as possible therapeutic options. The results here reflected provide 461 
stimulus for further in vitro and in vivo investigations to maximize the efficacy of 462 
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Table 1. Carbapenem MIC values (mg/L) with clinical and transformed bacterial strains used.  
 
a TAZ, tazobactam; SUL, sulbactam; CLA, clavulanic acid and LN, LN-1-255.  
 
b The four inhibitors were tested at 4 mg/L using K. pneumoniae clinical and transformed strains. Tazobactam and 
LN-1-255 were tested using transformed E. coli up to 4 mg/L; and tazobactam and LN-1-255 were tested up to 16 
mg/L using K. pneumoniae clinical and transformed strains.  
NA: Some combinations of carbapenems and inhibitors could not be performed due to intrinsic strain susceptibility. 
MICs using transformed E. coli were 16 mg/L for sulbactam and 16-128 mg/L for clavulanic acid, and using K. 
pneumoniae strains were 32-256 mg/L for both inhibitors. 
Data represent the means of three independent experiments.  




K. pneumoniae  clinical 
strain 
K. pneumoniae   
ΔompK35/36 
K. pneumoniae  
ΔompK35/36 (OXA-48) 
E. coli J53 
ΔompC/F 




4 mg/L b 16 mg/L 4 mg/L 16 mg/L 4 mg/L 16 mg/L 4 mg/L 16 mg/L 4 mg/L 16 mg/L 
Imipenem 64  64 0.5 0.5  128 128  0.25 0.25  1 1 
Imipenem + TAZ 64  32  0.5 0.25  128 128  0.25 0.125  1 0.5 
Imipenem + SUL 64 NA 0.5 NA 128 NA NA NA NA NA 
Imipenem + CLA 64 NA 0.5 NA 128 NA NA NA NA NA 
Imipenem + LN 16  4  0.5 0.25  32 16  0.25 0.25  0.5 0.125 
Meropenem 16 16 0.25 0.25 64 64 0.03 0.03 2 2 
Meropenem + TAZ 16 8 0.25 0.25 32 32 0.03 0.015 1 1 
Meropenem + SUL 16 NA 0.25 NA 32 NA NA NA NA NA 
Meropenem + CLA 16 NA 0.25 NA 32 NA NA NA NA NA 
Meropenem + LN 8 4 0.25 0.25 16 8 0.03 0.03 0.25 0.06 
Ertapenem 128 128 2 2 256 256 0.015 0.015 0.5 0.5 
Ertapenem + TAZ 128 32 2 1 256 128 0.015 0.007 0.5 0.25 
Ertapenem + SUL 128 NA 2 NA 256 NA NA NA NA NA 
Ertapenem + CLA 128 NA 2 NA 256 NA NA NA NA NA 
Ertapenem + LN 64 16 2 1 64 64 0.015 0.015 0.015 0.007 
 












             OXA-48   
Substrate Km  (µM) kcat (s
-1







Nitrocefin 65.7 ± 18.9 314.7 ± 18.9 4.79  
Imipenem 60.3 ± 12.4 1.5 ± 0.1 0.025  
Ertapenem 123.7 ± 36.2 0.3 ± 0.02 0.002  
Table 3. OXA-48 inhibition kinetics of LN-1-255 and tazobactam. 
 
 





































LN-1-255 0.003 ± 
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Figure 2. Progress curves of 200 µM nitrocefin hydrolysis with increasing inhibitor 
concentrations (0.2 µM to 3.3 µM LN-1-255 and 10 µM to 350 µM tazobactam) and a fixed 





Figure 3. Progress curves for determination of off-rates (koff) for OXA-48/LN-1-255 and 
controls (OXA-48 alone and LN-1-255 alone) with 200 µM of nitrocefin. OXA-48 was 
incubated with LN-1-255 to allow the formation of the acyl-enzyme adduct, then diluted to 




Figure 4. Progress curves for determination of turnover (tn). OXA-48 at 10 nM was incubated 







Figure 5. Carbapenemase OXA-48 from K. pneumoniae covalently modified by 
avibactam and LN-1-255. A,C) Crystal structure of OXA-48/avibactam adduct (PDB 
4S2K,
44
 2.1 Å). B,D) Proposed irreversible modification of OXA-48 by LN-1-255 
obtained by Molecular Docking studies. Hydrogen bonding and electrostatic 
interactions between the ligand and OXA-48 are shown as dashed blue lines. Relevant 
side chain residues are shown and labeled. Figure represented with PyMOL Molecular 
Graphics System.
53 
 
